By: Kristie L. Kahl, Darlene Dobkowski
Improved MRD Negativity: Adding Darzalex to the standard treatment of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone (VRd) significantly improved the rate of minimal residual disease (MRD) negativity. After 58.7 months of follow-up, MRD-negativity rates were 60.9% for the Darzalex group versus 39.4% for the VRd-only group.